Insider Transactions in Q3 2021 at Vir Biotechnology, Inc. (VIR)
Insider Transaction List (Q3 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 27
2021
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.38%
|
$0
$0.86 P/Share
|
|
Sep 22
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+6.91%
|
$8,000
$1.53 P/Share
|
|
Sep 21
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
4,125
-3.97%
|
$206,250
$50.0 P/Share
|
|
Sep 21
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,125
+3.82%
|
$4,125
$1.53 P/Share
|
|
Sep 17
2021
|
Vicki L Sato Director |
SELL
Open market or private sale
|
Direct |
15,174
-0.47%
|
$789,048
$52.69 P/Share
|
|
Sep 15
2021
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-2.3%
|
$245,000
$49.97 P/Share
|
|
Sep 07
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
4,125
-2.0%
|
$202,125
$49.5 P/Share
|
|
Sep 07
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,125
+3.82%
|
$4,125
$1.53 P/Share
|
|
Sep 01
2021
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-1.48%
|
$245,000
$49.52 P/Share
|
|
Sep 01
2021
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.19%
|
$5,000
$1.53 P/Share
|
|
Aug 30
2021
|
Janet Napolitano Director |
SELL
Open market or private sale
|
Direct |
1,435
-29.84%
|
$73,185
$51.15 P/Share
|
|
Aug 30
2021
|
Janet Napolitano Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,435
+22.98%
|
$58,835
$41.64 P/Share
|
|
Aug 25
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
2,750
-2.68%
|
$137,500
$50.0 P/Share
|
|
Aug 25
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,750
+2.61%
|
$2,750
$1.53 P/Share
|
|
Aug 24
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-1.36%
|
$66,000
$48.0 P/Share
|
|
Aug 24
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+1.34%
|
$1,375
$1.53 P/Share
|
|
Aug 23
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
13,750
-12.12%
|
$687,500
$50.0 P/Share
|
|
Aug 23
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,750
+10.81%
|
$13,750
$1.53 P/Share
|
|
Aug 23
2021
|
Steven J. Rice Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
10,000
-33.33%
|
$500,000
$50.0 P/Share
|
|
Aug 23
2021
|
Steven J. Rice Chief Administrative Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+25.0%
|
$120,000
$12.76 P/Share
|
|
Aug 19
2021
|
Vicki L Sato Director |
SELL
Open market or private sale
|
Direct |
15,174
-0.47%
|
$667,656
$44.94 P/Share
|
|
Aug 18
2021
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-4.38%
|
$210,000
$42.23 P/Share
|
|
Aug 18
2021
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.19%
|
$5,000
$1.53 P/Share
|
|
Aug 10
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-1.36%
|
$56,375
$41.0 P/Share
|
|
Aug 10
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+1.34%
|
$1,375
$1.53 P/Share
|
|
Aug 04
2021
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-4.38%
|
$170,000
$34.92 P/Share
|
|
Aug 04
2021
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.19%
|
$25,000
$5.17 P/Share
|
|
Jul 29
2021
|
Robert J More Director |
SELL
Open market or private sale
|
Direct |
11,670
-12.83%
|
$431,790
$37.11 P/Share
|
|
Jul 27
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-1.36%
|
$49,500
$36.72 P/Share
|
|
Jul 27
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+1.34%
|
$1,375
$1.53 P/Share
|
|
Jul 21
2021
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,630
-4.06%
|
$171,310
$37.44 P/Share
|
|
Jul 21
2021
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,630
+3.91%
|
$4,630
$1.57 P/Share
|
|
Jul 19
2021
|
Vicki L Sato Director |
SELL
Open market or private sale
|
Direct |
15,174
-0.46%
|
$561,438
$37.29 P/Share
|
|
Jul 15
2021
|
Robert J More Director |
SELL
Open market or private sale
|
Direct |
11,670
-20.23%
|
$408,450
$35.56 P/Share
|
|
Jul 13
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-1.36%
|
$49,500
$36.72 P/Share
|
|
Jul 13
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+1.34%
|
$1,375
$1.53 P/Share
|
|
Jul 07
2021
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-2.21%
|
$200,000
$40.54 P/Share
|
|
Jul 07
2021
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.19%
|
$25,000
$5.17 P/Share
|
|
Jul 01
2021
|
Robert J More Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,671
+3.38%
|
$71,853
$43.53 P/Share
|
|
Jul 01
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
33,412
+36.37%
|
-
|
|
Jul 01
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
4,000,000
-15.58%
|
-
|
|
Jul 01
2021
|
Robert Nelsen Director |
BUY
Other acquisition or disposition
|
Direct |
47,897
+36.36%
|
-
|
|
Jul 01
2021
|
Robert Nelsen Director |
SELL
Other acquisition or disposition
|
Indirect |
4,000,000
-15.58%
|
-
|
|
Jul 01
2021
|
Robert J More Director |
SELL
Open market or private sale
|
Direct |
11,670
-5.9%
|
$525,150
$45.25 P/Share
|